Can I read In vitro and in vivo anti-uveal melanoma activity of JSL-1, a novel HDAC inhibitor on EtoBox?

In vitro and in vivo anti-uveal melanoma activity of JSL-1, a novel HDAC inhibitor by Yun Wang; Maoxing Liu; Yanli Jin; Sheng Jiang; Jingxuan Pan is a Biochemistry, Genetics and Molecular Biology article available to read on EtoBox.

What is In vitro and in vivo anti-uveal melanoma activity of JSL-1, a novel HDAC inhibitor about?

Uveal melanoma (UM) is the most common intraocular malignant neoplasm in adults. Despite the availability of enucleation, radiation and chemotherapy, the prognosis of patients with metastasis remains poor. Therefore, novel effective therapies for patients with metastatic UM are urgently needed. In the present study, we demonstrated that JSL-1, a novel HDAC inhibitor, effectively inhibited the proliferation. JSL-1 induced apoptosis with increased expression of proapoptotic BH3-only protein BIM in UM cells. JSL-1 suppressed migration and invasion of UM cells with MMP-2 decreased. Furthermore, JSL-1 blocked the canonical Wnt/β-catenin pathway, impaired self-renewal capacity and decreased percentage of ALDH cells, thereby reflecting elimination of UM cancer stem-like cells (CSCs) which are believed seeds of metastasis. Importantly, JSL-1 potently inhibited the growth of uveal melanoma xenograft in NOD-SCID mice. These results suggested that JSL-1 may be a promising therapeutic agent for UM.

Who reads In vitro and in vivo anti-uveal melanoma activity of JSL-1, a novel HDAC inhibitor?

Author

Yun Wang; Maoxing Liu; Yanli Jin; Sheng Jiang; Jingxuan Pan

Publisher

Elsevier BV

Published

2017

Language

EN

Field

Biochemistry, Genetics and Molecular Biology (Life Sciences)